August 2025 in “The Journal of Sexual Medicine” Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.
December 2022 in “Journal of The European Academy of Dermatology and Venereology” The 7.1% withdrawal rate was in the oral finasteride group, not the topical one.
22 citations
,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
78 citations
,
December 2008 in “The Journal of Sexual Medicine” 5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction, but the exact reasons are unclear.
2 citations
,
March 2014 in “European Journal of Chemistry” Method measures tamsulosin and finasteride in medicine accurately.
June 2023 in “Clinica Chimica Acta” Finasteride and dutasteride effectively reduce DHT in hair, which may help evaluate their treatment success for hair loss.
19 citations
,
September 2009 in “Journal of Chemical & Engineering Data” Flutamide, dutasteride, and finasteride dissolve differently in supercritical carbon dioxide, with dutasteride dissolving the least.
1 citations
,
January 2009 in “CRC Press eBooks” Finasteride increases hair count and improves hair growth with low risk of side effects.
1 citations
,
August 2018 in “Journal of The American Academy of Dermatology” Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.
29 citations
,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
March 2026 in “Gazzetta Medica Italiana Archivio per le Scienze Mediche” Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
May 2008 in “10th European Congress of Endocrinology”
January 2025 in “Heliyon” Tamsulosin and finasteride have similar effects on blood sugar control in men with type 2 diabetes.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
3 citations
,
November 2018 in “The Journal of Clinical Psychiatry” Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.
February 2024 in “Urology” Certain medications, especially Paroxetine, Tamsulosin, and Finasteride, are linked to ejaculatory disorders.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
September 2003 in “Reactions Weekly”
April 2018 in “Expert Opinion on Drug Safety” Use finasteride over dutasteride for hair loss; consider topical treatments and weigh risks.
Three reliable methods were developed to measure Finasteride and Tamsulosin Hydrochloride in medicines.
July 2010 in “PharmacoEconomics & Outcomes News”
31 citations
,
September 2008 in “International Journal of Andrology” 5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
13 citations
,
May 2018 in “Urologic Oncology: Seminars and Original Investigations” Finasteride does not prevent bladder cancer.
A new method accurately measures Finasteride and Tamsulosin in tablets.
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
3 citations
,
January 2001 in “Cambridge University Press eBooks” Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.
These medications for BPH have known risks and may have new side effects.
May 2024 in “News Digital Object Group”